Drug interactions
Encorafenib + Palbociclib
Severity: Moderate
Encorafenib and Palbociclib: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Palbociclib is a weak to moderate CYP3A4 inhibitor and may increase encorafenib exposure. This could raise the risk of encorafenib toxicities such as QT prolongation and skin or ocular effects.
What this interaction means in plain words
Encorafenib and Palbociclib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Encorafenib belongs to Oncology; Palbociclib belongs to Oncology.
Why it happens
Palbociclib may inhibit CYP3A4, reducing encorafenib metabolism.
What to do
Monitor for encorafenib adverse effects and ECG/QTc and electrolytes. Consider reducing the encorafenib dose if toxicity develops.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Encorafenib and Palbociclib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Palbociclib
Other interactions of Encorafenib
Frequently asked questions
Can I take Encorafenib with Palbociclib?
MediHelp rates the interaction as moderate. Encorafenib and Palbociclib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Palbociclib is a weak to moderate CYP3A4 inhibitor and may increase encorafenib exposure. This could raise the risk of encorafenib toxicities such as QT prolongation and skin or ocular effects.
How serious is the interaction between Encorafenib and Palbociclib?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor for encorafenib adverse effects and ECG/QTc and electrolytes. Consider reducing the encorafenib dose if toxicity develops.
What other medicines interact with Palbociclib?
MediHelp also lists interactions of Palbociclib with, for example, Apalutamide, Atazanavir, Carbamazepine. The full list is on the Palbociclib page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
